Category Archives: Nevada Stem Cells

This fall brings a fresh crop of documentary podcast series, many of them timely but not overfamiliar. Tunnel 29, the new season of BBC Radio 4s Intrigue series, reported and narrated by Helena Merriman, tells the true story of Joachim Randolph, who, in the early sixties, as a twenty-two-year-old engineering student in communist East Germany, escaped to West Berlinand then dug a tunnel back into East Germany, beneath the Berlin Wall, to help other refugees escape. Theres plenty of spade-and-dirt action, and panting, in this Stasi-haunted dramatization of heroism, as Randolph and an unlikely team of helpers burrow toward an East German basement. But, unlike last seasons narratively unnerving Intrigue: The Ratline (upsetting Schloss, Nazi horrors, typewriter sounds), Tunnel 29 finds a deft balance of realism and drama in its narration, performance, and sound design. A surprisingly lovely toast-eating scene, featuring pineapple marmalade and freedom, packs an unexpected punch.

Bad Batch, from the reporter Laura Beil, could fit into two genres. The first is medical true crime, as pioneered by Beil in her previous series, Dr. Death, about a horrifically injurious Texas neurosurgeon; the second is the startup cautionary tale, la The Dropout, about Elizabeth Holmes and Theranos. Bad Batch delves into the promising but murky realm of stem-cell medical treatments, beginning with a deep dive into an incident in which treatments using a bad batch of stem cells, originating from a single company, almost killed several people. Beil, who hosts, takes us through backstories involving health-care fraud, a Ponzi scheme, and high-pressure stem-cell educational seminars, which hoodwink vulnerable people into spending thousands on dubious therapies. Four episodes in, Bad Batch has enlightened me more about fraudsters than science; future episodes may go further to sort out stem-cell fact from fiction. Meanwhile, Im pleased that this series, produced, like Dr. Death, by the sensationalism-prone hitmaker Wondery, so far avoids the noir impulses of its predecessor.

Like Nashville Public Radios excellent The Promise, about a public-housing gambit in Nashville, the new season of USA Todays The City, featuring Robin Amer and Anjeanette Damon, tells the story of a fast-changing city via one vivid enclave within it; here, its Reno, Nevada, and its strip clubs. A tech boom in Reno, near Elon Musks Tesla Gigafactory 1, has driven a real-estate frenzy and a gentrification battle, and The City takes us inside itso far, to city-council meetings, private-eye stakeouts, and a newly vulnerable residential hotel. The reporting has a sensitive ear for distinctive characters, like Velma Shoals, a hotel resident determined to save her home, and Kamy Keshmiri, a straight-talking Reno native and former athlete whose family owns the hotel and a strip club. (Its sad that youre bringing private investigators in to look at boobs, he says at one point, about officials hoping to catch illegal activity at the club. Yeahtheres boobs.) The series provides an impressively sweeping but intimate look at an American city; I began it knowing little about Reno and emerged wanting to know everything.

Go here to read the rest:
Three Podcasts to Listen to in November - The New Yorker

Since Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership of both companies.

Valuation & Earnings

Table 1 highlights Spectrum Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc.s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows the return on equity, net margins and return on assets of the two firms.

Risk and Volatility

Spectrum Pharmaceuticals Inc. is 154.00% more volatile than Standard and Poors 500 due to its 2.54 beta. Competitively, Brainstorm Cell Therapeutics Inc.s beta is 1.19 which is 19.00% more volatile than Standard and Poors 500.

Analyst Ratings

The following table given below contains the ratings and recommendations for Spectrum Pharmaceuticals Inc. and Brainstorm Cell Therapeutics Inc.

The upside potential is 400.00% for Spectrum Pharmaceuticals Inc. with average target price of $41. Meanwhile, Brainstorm Cell Therapeutics Inc.s average target price is $9, while its potential upside is 131.96%. The data from earlier shows that analysts view suggest that Spectrum Pharmaceuticals Inc. seems more appealing than Brainstorm Cell Therapeutics Inc.

Institutional and Insider Ownership

Roughly 75.6% of Spectrum Pharmaceuticals Inc. shares are held by institutional investors while 11.4% of Brainstorm Cell Therapeutics Inc. are owned by institutional investors. Spectrum Pharmaceuticals Inc.s share held by insiders are 1.3%. Competitively, insiders own roughly 0.6% of Brainstorm Cell Therapeutics Inc.s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Spectrum Pharmaceuticals Inc. has -13.37% weaker performance while Brainstorm Cell Therapeutics Inc. has 12.96% stronger performance.

Summary

Spectrum Pharmaceuticals Inc. beats Brainstorm Cell Therapeutics Inc. on 8 of the 10 factors.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkins lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

More:
Comparison of Spectrum Pharmaceuticals Inc. (SPPI) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - MS Wkly

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) and TG Therapeutics Inc. (NASDAQ:TGTX) compete with each other in the Biotechnology sector. We will analyze and contrast their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation & Earnings

In table 1 we can see Spectrum Pharmaceuticals Inc. and TG Therapeutics Inc.s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us the net margins, return on assets and return on equity of both companies.

Volatility & Risk

Spectrum Pharmaceuticals Inc. is 154.00% more volatile than Standard and Poors 500 because the company has a beta of 2.54. From a competition point of view, TG Therapeutics Inc. has a 2.32 beta which is 132.00% more volatile compared to Standard and Poors 500.

Analyst Ratings

The table delivered features the ratings and recommendations for Spectrum Pharmaceuticals Inc. and TG Therapeutics Inc.

Meanwhile, TG Therapeutics Inc.s average price target is $20, while its potential upside is 284.62%.

Institutional and Insider Ownership

Roughly 75.6% of Spectrum Pharmaceuticals Inc. shares are held by institutional investors while 59% of TG Therapeutics Inc. are owned by institutional investors. Insiders held roughly 1.3% of Spectrum Pharmaceuticals Inc.s shares. Insiders Comparatively, held 0.4% of TG Therapeutics Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Spectrum Pharmaceuticals Inc. had bearish trend while TG Therapeutics Inc. had bullish trend.

Summary

On 8 of the 10 factors Spectrum Pharmaceuticals Inc. beats TG Therapeutics Inc.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkins lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkins lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program in the field of hematological malignancies; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. is headquartered in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

View post:
Spectrum Pharmaceuticals Inc. (SPPI) and TG Therapeutics Inc. (NASDAQ:TGTX) Comparison side by side - MS Wkly

Since Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) and Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation of both companies.

Earnings and Valuation

Table 1 demonstrates Spectrum Pharmaceuticals Inc. and Rocket Pharmaceuticals Inc.s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Risk & Volatility

Spectrum Pharmaceuticals Inc. has a beta of 2.54 and its 154.00% more volatile than Standard & Poors 500. In other hand, Rocket Pharmaceuticals Inc. has beta of 2.66 which is 166.00% more volatile than Standard & Poors 500.

Analyst Recommendations

The next table highlights the given recommendations and ratings for Spectrum Pharmaceuticals Inc. and Rocket Pharmaceuticals Inc.

Meanwhile, Rocket Pharmaceuticals Inc.s consensus target price is $37, while its potential upside is 167.15%.

Insider & Institutional Ownership

The shares of both Spectrum Pharmaceuticals Inc. and Rocket Pharmaceuticals Inc. are owned by institutional investors at 75.6% and 87.9% respectively. About 1.3% of Spectrum Pharmaceuticals Inc.s share are owned by insiders. Competitively, insiders own roughly 1.6% of Rocket Pharmaceuticals Inc.s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Spectrum Pharmaceuticals Inc.s stock price has smaller decline than Rocket Pharmaceuticals Inc.

Summary

On 5 of the 8 factors Spectrum Pharmaceuticals Inc. beats Rocket Pharmaceuticals Inc.

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkins lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under preclinical development. The company has collaboration agreements with Lund University, Sweden; and Centro de Investigaciones Energticas, Medioambientales y Tecnolgicas. The company is headquartered in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Original post:
Spectrum Pharmaceuticals Inc. (SPPI) and Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) Comparison side by side - CryptoCoinsTribune

As an interventional pain management specialist with over 25 years of experience, Dr. Crispino Santos is a leader of medical innovations that provide longer lasting solutions for chronic pain and specialized treatments to help reduce the problems associated with injuries and degenerative diseases through Stem Cell Therapy in Las Vegas, NV.

Dr. Santos is the President and medical director of both the Regenerative Cell Institute (RCI) and Interventional Pain Medicine (IPM). He attended medical school at the Far Eastern University in Manila, Philippines, and did his post-doctoral residency training in general surgery and anesthesiology at King Drew Medical Center in Los Angeles, California. He also completed one year of advanced anesthesiology fellowship at University of South Florida-Tampa General Hospital in Tampa, Florida. He graduated and is a recipient of Winthrop Stearns Scholar and Rolando Solis Cardiology Award in 1979.

Dr. Santos first practiced medicine in Mason City, Iowa where he worked for nine years and started the cardiac anesthesia program and established the Pain Management Center at St. Joseph Mercy Hospital.In February 1998, Dr. Santos moved to Las Vegas, Nevada and joined Nevada Orthopedic and Spine Center. There, he began his full-time practice as an interventional pain physician. He founded Regenerative Cell Institute of Las Vegas, Nevada in 2013 and opened the Institutes second location in Mason City, Iowa in 2014. In February 2017, he extended his practice to his native home, Philippines, where he performs procedures at the Panay Healthcare Hospital in Kalibo, Aklan Province, Philippines.

Dr. Santos is board-certified in both anesthesiology and pain medicine by the American Board of Anesthesiology, the American Board of Pain Medicine, and the American Board of Pain Management. He is also board certified by the American Board of Interventional Pain Physicians and a Fellow of Interventional Pain Practice. Additionally, he is an active member of the World Institute of Pain, the International Spine Intervention Society, the American Society of Interventional Pain Physicians, the International Neuromodulation Society, the American Academy of Pain Medicine, the American Association of Pain Management in Ultrasound, the American Society of Cosmetic Physicians, the American Academy of Anti-Aging Medicine, the International Society of Plastic and Regenerative Surgeons, and the American Association of Orthopedic Medicine.

He specializes in minimally invasive interventional procedures for the treatment of spinal pain and other complex chronic pain conditions. Dr. Santos unparalleled expertise in minimally invasive injection techniques, utilizing live image guidance, allows him to administer the biologic solutions are placed precisely in the areas of tissue damage. Using the latest stem cell research and cutting-edge regenerative medical techniques, he performs the most advanced regenerative cell treatments for an array of medical conditions including arthritis, joint injuries, spinal pain, chronic pain conditions, neurological conditions, auto-immune diseases, and aesthetics. He has performed several thousands of interventional pain procedures, have trained other doctors, given lectures, and treated patients locally and internationally.

He is always researching the most advanced, safe, and effective therapies to improve and prolong patients lives using the most natural way of healing.

About Regenerative Cell Institute

With locations in Las Vegas, Nevada, and Mason City, Iowa, the Regenerative Cell Institute (RCI) has changed the practice of traditional medicine by revolutionizing pain management and regenerative medical treatments to reduce symptoms associated with the diseases of aging. Combining cutting-edge regenerative medical techniques utilizing stem cells and high-density activated platelet-rich plasma (PRP) with several stem cell procedures, Dr. Santos and his team offer the most advanced regenerative cell treatments for an array of medical conditions including arthritis, joint injuries, spinal pain, chronic pain conditions, neurological conditions, auto-immune diseases, sexual wellness, and aesthetics.

Dr. Santos splits his time between both offices, performs all procedures, and offers customized treatment options and care plans. He carefully evaluates each patients condition and body composition to determine the best stem cell extraction technique, harvesting process, and treatment plan to ensure patients receive the highest concentrations of stem cells to spark the bodys natural healing and rejuvenation processes. While other doctors often require multiple appointments and procedures which drives up patient costs, Dr. Santos patients enjoy a 90% success rate after one treatment*; 10-20% of patients require a booster dose** to achieve optimal results.

Why Choose RCI?

We provide the highest quality patient care available with over 90% satisfaction rate.

View post:
Stem Cell Therapy | Las Vegas, NV

Lyme disease is an incredibly debilitating disease. Just ask former model and Real Housewife of Beverly Hills star Yolanda Hadid. She knows all too well the pain and suffering that Lyme disease can inflict on a person.

However, after dealing with this disease for over six years, Hadid is finally feeling healthy. How is this possible? Yolanda Hadid received breakthrough stem cell treatments. The result: shes finally in remission.

Hadid had been struggling with some extremelydebilitating symptoms from her Lyme disease, including:

In 2015, she started receiving stem cell treatments. These treatments have allowed her immune system to rebuild itself. Her symptoms have decreased tremendously. She is now in remission and is finally starting to feel healthy again.

The key to this transformation was the latest in stem cell research and treatments. The latest studies look promising, and researchers hope that stem cells will have a profound impact on the following diseases and conditions:

Studies are being done on these and a number of other conditions to see if stem cells can help.

Stem cells are young, healthy cells that replace old cells or cells that have died. They help the body rebuild and repair itself.

In addition to treating diseases, stem cells can help researchers study diseases and find both stem cell and non-stem cell-related cures.

Have you been struggling with a debilitating condition like Lyme disease? We welcome you to find out more about stem cell research and treatments. With the latest stem cell technology, you may end up like Yolanda Hadid feeling like youre finally on the road to recovery.

Would you like to learn more about the power of stem cells? Contact us today for more information about the conditions we can treat.

DYNAMIC Stem Cell Therapy2551 N Green Valley ParkwayBuilding C, Suite 305C Henderson, Nevada 89014702-547-6565

Here is the original post:
Yolanda Hadids Lyme Disease Battle - Nevada Stem Cell ...

Our Technology

Early stem cell research has generally been connected with the controversial utilization of embryonic stem cells. The new focus is on non-embryonic adult mesenchymal stem cells which are discovered in an individual's own blood, bone marrow, and fat.

Learn More

Treatment Process

You have made an important decision to have an stem cell deployment. Its exciting that these devices are presently accessible for therapeutic utilization. Stem cell therapy with your own stem cells might possibly be the next critical development in medicine

Learn More

Hitting retirement age or being blindsided by a sports injury doesnt mean putting your life on hold. At the Regenerative Medicine Institute of Nevada, we understand how better mobility improves quality of life. That's why we offer treatments that can help you achieve better ways to relieve chronic pain, encourage natural tissue healing and faster recovery times.

We offer stem cell therapy in Las Vegas NV to patients to treat a range of conditions. These treatments include the following:

At the Regenerative Medicine Institute of Nevada, only trained and experienced staff perform these procedures. If you need more help in deciding whether stem cell treatment is right for you, talk to us.

Go here to read the rest:
Regenerative Medicine Institute of Nevada RMinLasVegas ...

As a relatively new and rapidly evolving field of medicine, regenerative medicine uses adult stem cells to help the body regenerate, rebuild, and heal itself. It will give patients suffering from many diseases like Diabetes, Neuropathy, Cardiovascular disease, and Erectile Dysfunction new options of treatment.

Las Vegas, Nevada is already part of the stem cells revolution. Regenerative Medicine Institute of Nevada is highly dedicated to clinical research and the progression of regenerative medicine.

Stem Cells can be used for pain management trough minimally invasive stem cell therapies however therapies are not legally approved for Las Vegas. Stem cells Transplant institute in Costa Rica has expertise in stem cell therapy and stem cell extraction techniques. The institute offers the most innovative stem cell therapy procedures to heal the body, naturally rejuvenate tissue, and prevent disease.

The Stem Cells Transplant Institute of Costa Rica specializes in the legal treatment of Knee Injury, Chronic Obstructive pulmonary disease, Diabetes, Neuropathy, Cardiovascular Disease, Alzheimer, Parkinson, Multiple Sclerosis, Lupus, Rheumatoid Arthritis, Myocardial infarction, Critical limb isquemia, Erectile Dysfunction and Osteoarthritis.

Stem Cells transplant Institute specializes in all areas of regenerative medicine, using the most advanced stem cell extraction methods and proprietary concentration techniques to deliver the best stem cell therapy, ensuring our patients from Mogul, Incline Village, Mount Charleston, Blue Diamond, Kingsbury and many other places to receive the highest level of health care. Apply now

Visit link:
Las Vegas Stem Cells Treatment, Nevada, Legal, Reno, Mogul ...

Longtime researcher Janice Pluth has worked with incredible students during her cancer and radiation-focused research at Lawrence Berkeley National Laboratory in Northern California. When she decided to begin teaching, UNLVs nationally recognized student diversity and Top Tier aspirations led her to Southern Nevada and the universitys School of Allied Health Sciences.

I have led many research projects during my career and have interacted with excellent students who were dedicated to helping me, but did not have an opportunity to formally teach. When considering where to go, I was drawn to UNLV because of its student diversity, which brings uniqueness to the university, and its plan to become a Top Tier university and earn recognition as a research institution. I am looking forward to teaching radiation biology this fall.

I grew up in Rochester, Minnesota, and lived in the state until I obtained my bachelors at the University of Minnesota.

My long-term interests are to understand the mechanisms that contribute to the etiology of radiation-induced carcinogenesis. I have a career-long interest in understanding the repair of DNA double-strand breaks, the most damaging lesion induced by radiation. My work has focused on elucidating the proteins, pathways, and networks critical to the damage response. Im also interested in better understanding individual differences in responses to damages as well as differences in cellular responses, particularly stem cells.

One of the biggest challenges in my field of research is finding biomarkers that a clinic can use to predict how a person will respond to therapy. There are many researchers working with biomarkers to predict sensitivity to radiation, but these have not yet found widespread clinical use. Innovations in this area will help to move to a more personalized radiation treatment.

Two people were key to my career path. The first was my undergraduate microbiology teacher. He was able to make complex concepts easy to understand and saw potential in me as a strong researcher that I, at that time, did not see in myself. The other is Dr. Betsy Hirsch, who I worked with as a work-study student. She was then and still is now the director of the cytogenetics laboratory at the University of Minnesota. I was able to become fully immersed in a large twin study that stimulated me to better understand DNA repair and why individuals with the same genes may respond differently to the same exposures.

My proudest moment (so far) is my son graduating from high school.

If I could fix one thing two, actually in the world, it would be to ensure everyone had equal opportunities in life, and a safe environment in which to grow and live.

People might be surprised to learn I have a black belt in tae kwon do.

I want to be known for taking an active interest in my students; as one who listens, relays information in an understandable manner, and helps them achieve their goals and recognize their potentials.

Years ago, my sons happy meal contained a yellow toy planet connected to a space rover with the letters NASA on the side. I set it on my desk when I was writing my first NASA research grant. After I got the grant, the toy became my lucky charm. NASA has been very supportive of my work and the lucky charm has had a consistent place on my desk ever since.

I admire my mother-in-law. She is honest, unselfish, kind, and non-judgmental. She often reminds people who are critical of others that you have not walked in their shoes. She has always taken the high road and forgiven people even those many of us would have a hard time forgiving. She inspires me to be a better person.

I enjoy martial arts, hiking, bonsai gardening, painting, and drawing.

I rock climb and a few times Ive gotten into situations that are a bit intimidating, but I really enjoy it.

Be a therapist or counselor. Ive worked for a number of years on a crisis hotline as a volunteer. If I wasnt conducting research, Id like to help people in this way.

Here is the original post:
New Face: Janice Pluth - UNLV NewsCenter

Dont count on seeing Cody Garbrandt in action this summer.

No Love was going to defend his Ultimate Fighting Championship (UFC) bantamweight title against T.J. Dillashaw this Saturday night (July 8). It was set to headline UFC 213 in Las Vegas, Nevada.

Garbrandts back issues couldnt heal in time to make the bout happen at this time. Many have wondered when No Love will be cleared. Garbrandt told the FOX Sports crew on TUF Talk that November is probably the earliest month he can return (via MMA Weekly):

I would say earliest is November. Give my back enough time [to heal]. I did two procedures, one here in the States that they told me I was going to be fine after the stem cells. I went back to training, I lasted for three days and I was in the worst pain. I couldnt even walk. Then they flew me over to Germany and that took the pain, the sciatic [nerve] down away, but Im still not able to do any of my life, full fighting. So Im just making sure my back holds up so I dont jump into a fight and have to pull out. Its not something I want to have to do. So hopefully November Ill be ready to go.

Read more from the original source:
Cody Garbrandt Likely Won't Return Until at Least November - MMA News